Genprex Inc. (NASDAQ: GNPX) Establishing Itself as a Trailblazer in Breakthrough Cancer Treatments

Pharmaceutical companies are now employing advanced medical breakthroughs and new technologies, including gene therapies and nanoparticle engineering, to fight every type of cancer.

• Gene therapies are being developed to more effectively target the treatment of cancer.
• Non-small cell lung cancer (NCSLC) is the leading cause of cancer death.
• Genprex Inc. is advancing Oncoprex, shown to benefit lung cancer patients in early trials.

A multiplicity of potential breakthrough treatments to fight cancer are in varying stages of clinical development, and many are focused on the promise of advanced gene therapies. Genprex Inc. (NASDAQ: GNPX) is working to bring its potentially life-changing immunogene therapy, Oncoprex, to market. Pfizer Inc. (NYSE: PFE) just gained Food and Drug Administration (FDA) approval for TRAZIMERA(TM), and Tocagen Inc. (NASDAQ: TOCA) is studying Toca 511. Novartis AG (NYSE: NVS) scientists are exploring immunotherapy matchmaking. Other biotechnology companies such Audentes Therapeutics Inc. (NASDAQ: BOLD) are developing innovative gene therapy products for patients living with life-threatening rare diseases.